Американское общество гирудотерапии

Genetically Encoded Multivalent Elastin-Like Polypeptide-Haemadin Fusion Proteins for Prolonged Antithrombotic Protection

Research article published in Biomacromolecules (2026)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportРазработка лекарственных препаратовКлинические исследованияБезопасность и инфекционный контрольФармакология секрета слюнных желёзYang H et al. · Biomacromolecules, 2026

Abstract

The clinical application of peptide therapeutics is often constrained by their short plasma half-life, necessitating frequent administration and resulting in undesirable pharmacokinetic fluctuations and side effects. Here, we developed a genetically encodable multivalent fusion protein platform that combines haemadin, a selective thrombin inhibitor derived from terrestrial leeches, with an elastin-like polypeptide (ELP) partner via factor Xa (FXa)-cleavable peptide linkers. This platform enables tunable drug loading, long-term release, and stimuli-responsive activation of antithrombotic activity. After subcutaneous injection, the fusion protein undergoes temperature-triggered ELP condensation to form an in situ depot that slowly releases an inactivated prodrug, which remains inert in circulation until thrombus-associated FXa cleave the linker to liberate active haemadin on demand. We achieved high-yield expression and facile nonchromatographic purification of the fusion protein. Subcutaneous administration resulted in significant prolongation of antithrombotic protection postinjection. This approach holds strong potential to enhance the safety, efficacy, and dosing convenience of peptide therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsElastinAnimalsRecombinant Fusion ProteinsPeptidesFibrinolytic AgentsHumansThrombosisMiceElastin-Like PolypeptidesFactor Xa

Резюме

The clinical application of peptide therapeutics is often constrained by their short plasma half-life, necessitating frequent administration and resulting in undesirable pharmacokinetic fluctuations and side effects.

Почему это важно для гирудотерапии

This study developed a genetically encodable multivalent fusion protein platform combining haemadin—a selective thrombin inhibitor derived from terrestrial leeches—with an elastin-like polypeptide partner to provide prolonged, stimuli-responsive antithrombotic protection. After subcutaneous injection, the fusion protein forms a depot that slowly releases an inactivated prodrug, which is liberated by thrombus-associated factor Xa to produce active haemadin on demand. This research is directly relevant to the American Society of Hirudotherapy and leech secretome research, as it leverages a leech-derived bioactive compound for innovative antithrombotic drug delivery. However, the abstract does not specify the study's experimental model or clinical stage, and the work involves engineered fusion proteins rather than live hirudotherapy or crude leech extracts.

Цитирование

Genetically Encoded Multivalent Elastin-Like Polypeptide-Haemadin Fusion Proteins for Prolonged Antithrombotic Protection

Yang H et al. · Biomacromolecules, 2026

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.